<DOC>
	<DOCNO>NCT02037191</DOCNO>
	<brief_summary>Alopecia areata ( AA ) auto immune disorder . Treatment severe type remain difficult rate hair regrowth lower 10 % . This RCT ass safety efficacy methotrexate alone associate low dos prednisone versus placebo treatment severe type AA .</brief_summary>
	<brief_title>The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade</brief_title>
	<detailed_description>Background : Alopecia areata ( AA ) auto immune disorder . Chronic severe type AA major impact patient ' quality life . Treatment severe type AA include phototherapy , pulse IV corticosteroid , topical immunotherapy . These treatment poorly effective severe type AA , since rate hair regrowth remain low 10 % . Methotrexate immunosuppressant use many autoimmune skin disorder . Aim : To assess safety efficacy methotrexate versus placebo treatment severe type AA . Design : Patients randomly assign receive methotrexate 20 25 mg / week 6 month . Patients experience least 25 % hair regrowth 5 month continue methotrexate placebo month 6 end study ( month 12 ) . Non responder patient randomize receive either methotrexate alone associate prednisone 0.3 mg/Kg/day month 6 end study ( month 12 ) . Study Design Primary outcome Rate complete almost complete hair regrowth month 12 evaluation patient treat methotrexate placebo randomize month 5 evaluation staid initial group randomization Secondary outcomes 1 . Rate Global Regrowth Assesment ( GRA ) month 6 12 . 2 . Delay hair regrowth 3 . Rate relapse 4 . Quality life 5 . Safety Arm description Arm A : methotrexate 20 25 mg / week 6 month . Arm B placebo Patients experience least 25 % hair regrowth month 5 evaluation continue methotrexate placebo month 6 end study ( month 12 ) . Non responder patient arm A B re-randomized receive month 6 end study ( month 12 ) : - methotrexate alone - methotrexate associate prednisone 0.3 mg/Kg/day 10 A study population Adult patient severe type AA evolve without hair regrowth least 6 month despite previous treatment impaired quality life Eligibility criterion Inclusion criterion 1. age 18 TO 70 year old 2. informed consent , 3. severe type AA define : 3.1 - AA totalis universalis 3.2 - evolve 6 month despite previous treatment include photothérapy ( PUVA oru UVB ) , application super potent topical corticosteroid ( clobetasol propionate ) , application minoxidil 5 % , IV pulse corticosteroid 3.3 - DLQI score inferior equal 10 Non inclusion criterion - Pregnant breast feed woman - VIH + patient - active hepatitis B C - treatment immunosuppressant ( ciclosporine , mycophénolate mofetil , cyclophosphamide , azathioprine , méthotrexate ) within 2 month inclusion - severe cardiac arythma severe cardiac insufficiency severe coronary disease - liver disorder - alcool consumption - renal failure - Severe diabetes mellitus - past history severe infection - past history néoplasiae ( exclude BCC ) , - Karnofsky index &lt; à 50 % - severe lung disorder - mental impairment - symptomatic osteoporosis - blood cytopénia ( hémoglobine &lt; 10 g/l ; leucocytes &lt; 3000/mm3 , platelet &lt; 100 000/mm3 ) - albuminémia &lt; 25 g/l</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1. age 18 70 year old 2. informed consent , 3. severe type AA define : 3.1 AA totalis universalis 3.2 evolve 6 month despite previous treatment include photothérapy ( PUVA oru UVB ) , application super potent topical corticosteroid ( clobetasol propionate ) , application minoxidil 5 % , IV pulse corticosteroid 3.3 DLQI score superior equal 10 Pregnant breast feed woman VIH + patient active hepatitis B C treatment immunosuppressant ( ciclosporine , mycophénolate mofetil , cyclophosphamide , azathioprine , méthotrexate ) within 2 month inclusion severe cardiac arythma severe cardiac insufficiency severe coronary disease liver disorder alcool consumption renal failure Severe diabetes mellitus past history severe infection past history néoplasiae ( exclude BCC ) , Karnofsky index &lt; à 50 % severe lung disorder mental impairment symptomatic osteoporosis blood cytopénia ( hémoglobine &lt; 10 g/l ; leucocytes &lt; 3000/mm3 , platelet &lt; 100 000/mm3 ) albuminémia &lt; 25 g/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ALOPECIA AREATA</keyword>
	<keyword>TREATMENT METHOTREXATE</keyword>
</DOC>